SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by GlaxoSmithKline plc on May 4, 2021, covering the month of May 2021. The filing serves as a notification to the market in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R regarding the Company's total voting rights and capital structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the Company's issued share capital as of April 30, 2021:
- Total issued shares: 5,386,650,226 Ordinary Shares of 25 pence each.
- Treasury shares held: 355,205,950 Ordinary Shares.
- Total voting rights: 5,031,444,276.
No material changes to financial performance or operational status are reported in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of share capital and voting rights.
Key Facts for Investor Verification
- Verify the total voting rights denominator (5,031,444,276) for calculating disclosure thresholds under FCA rules.
- Confirm the number of shares held in Treasury (355,205,950) as of April 30, 2021.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly reports for performance metrics.